Bayesian Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Bayesian Capital Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,425	Closed	-$381K	–	519
2021 Q1	$381K	Buy	3,425 +2,062	+151%	+$271K	0.09%	294
2020 Q4	$145K	Sell	1,363 -12,904	-90%	-$1.72M	0.04%	402
2020 Q3	$1.99M	Buy	+14,267	New	+$2.97M	0.49%	44
2020 Q2	–	Sell	-4,233	Closed	-$378K	–	636
2020 Q1	$378K	Buy	+4,233	New	+$261K	0.08%	372
2016 Q3	–	Sell	-883	Closed	-$98K	–	425
2016 Q2	$98K	Buy	+883	New	+$107K	0.06%	364

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bayesian Capital Management's INO Position: Q2 2021 in Review

Bayesian Capital Management sold out of Inovio Pharmaceuticals (INO) in Q2 2021, closing a stake of 3,425 shares — an estimated $381K sold.

Bayesian Capital Management first reported a position in INO in Q2 2016 and held it in 5 quarters. The position peaked at $1.99M in Q3 2020. 211 funds tracked by Wall St. Rank hold INO as of Q2 2021.

Bayesian Capital Management reported no remaining Inovio Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Bayesian Capital Management sold 3,425 Inovio Pharmaceuticals shares in Q2 2021, an estimated $381K.
Bayesian Capital Management first reported a position in Inovio Pharmaceuticals in Q2 2016 and held it in 5 quarters.
Bayesian Capital Management's Inovio Pharmaceuticals position peaked at $1.99M in Q3 2020.
211 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2021.

Based on Bayesian Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.